First Brands Group debt targeted by Apollo Global Management - report
Investing.com - Truist Securities initiated coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and a $100.00 price target on Wednesday. The biotech company, currently trading at $23.78, has seen its stock decline over 55% year-to-date, according to InvestingPro data.
The research firm highlighted Janux’s proprietary platforms, TRACTr and TRACIr, which it believes can overcome historical limitations of T-cell engagers in solid tumors by improving safety and efficacy through tumor-activated masking. InvestingPro data shows the company maintains a strong financial position with cash exceeding debt and a healthy current ratio of 47.03.
Truist identified lead asset JANX007 as having best-in-class potential in prostate cancer treatment, noting that multiple readouts expected across 2025 create a catalyst-rich year ahead for the company.
The firm emphasized that Janux’s masking technology offers a differentiated approach to both efficacy and safety in areas where many competitors have encountered difficulties.
Truist Securities expects key data updates in the second half of 2025, which it believes could drive meaningful upside for investors in the biotechnology company.
In other recent news, Janux Therapeutics has been the focus of several analyst reports and corporate developments. Stifel has resumed coverage on Janux Therapeutics with a Buy rating, citing the company’s innovative cancer treatment platform and setting a price target of $45.00. Guggenheim also initiated coverage with a Buy rating and a $72.00 price target, highlighting the potential of Janux’s JANX007 therapy for metastatic castration-resistant prostate cancer. Piper Sandler joined in by initiating coverage with an Overweight rating and a price target of $42.00, despite noting weakened investor sentiment towards Janux in 2025. Raymond James has rated the company as Outperform, with a $65.00 price target, based on promising results from higher doses of JANX007 in clinical trials.
In addition to analyst activities, Janux Therapeutics held its 2025 Annual Meeting of Stockholders. During the meeting, three Class I directors were elected, including David Campbell, Ph.D., Ron Barrett, Ph.D., and Winston Kung, who will serve until 2028. The meeting also included the ratification of the company’s independent registered public accounting firm and approval of executive compensation. The company decided on the frequency of future stockholder votes on executive pay. These developments indicate ongoing strategic movements within Janux Therapeutics as the company continues to advance its oncology therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.